In this context, local progression at one site after a good response to osimertinib makes good clinical sense. Given that the next line of therapy is chemotherapy, being able to continue the TKI as long as possible while addressing oligoprogression with RT for local control is appealing. However, we...

If osimertinib is effective at all other sites of disease (and has been well tolerated), local therapy to an isolated site of progression is an appealing option. SBRT or other ablative techniques or potentially surgical resection can help prolong the time on TKI therapy. We are learning that progres...